Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Zhengyu Jin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6179-9632; OpenAlex author ID A5078134324. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers

Papers 15

  1. Comparison of Perfusion CT and Conventional Thin-slice Multiphase CT in the Diagnosis of Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.acra.2025.03.049↗
  2. Erratum: Chinese expert consensus on imaging assessment of pancreatic ductal adenocarcinoma (PDAC) resectability. Last author DOI 10.1097/jp9.0000000000000235↗
  3. Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based cont… Co-author DOI 10.1007/s00259-024-06617-w↗
  4. Quantitative MR imaging biomarkers for distinguishing inflammatory pancreatic mass and pancreatic cancer-a systematic review and meta-analysis. Last author DOI 10.1007/s00330-024-10720-9↗
  5. Computed Tomography-based Radiomics Evaluation of Postoperative Local Recurrence of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.acra.2022.05.019↗
  6. Optical magnetic multimodality imaging of plectin-1-targeted imaging agent for the precise detection of orthotopic pancreatic ductal adenocarcinoma in mice. Co-author DOI 10.1016/j.ebiom.2022.104040↗
  7. Distinguishing pancreatic cancer and autoimmune pancreatitis with in vivo tomoelastography. Co-author DOI 10.1007/s00330-020-07420-5↗
  8. Assessment of Response to Chemotherapy in Pancreatic Cancer with Liver Metastasis: CT Texture as a Predictive Biomarker. First author DOI 10.3390/diagnostics11122252↗
  9. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Co-author DOI 10.1016/j.ejrad.2019.02.009↗
  10. Differentiation of atypical non-functional pancreatic neuroendocrine tumor and pancreatic ductal adenocarcinoma using CT based radiomics. Co-author DOI 10.1016/j.ejrad.2019.05.024↗
  11. Identification of key pathways and gene changes in primary pancreatic stellate cells after cross-talk with pancreatic cancer cells (BXPC-3) using bioinformatic… Co-author DOI 10.4149/neo_2018_180925n714↗
  12. Image quality of mean temporal arterial and mean temporal portal venous phase images calculated from low dose dynamic volume perfusion CT datasets in patients … Co-author DOI 10.1016/j.ejrad.2016.09.024↗
  13. CT Imaging Biomarkers Predict Clinical Outcomes After Pancreatic Cancer Surgery. Co-author DOI 10.1097/md.0000000000002664↗
  14. Clinical Value of Dual-energy CT in Detection of Pancreatic Adenocarcinoma: Investigation of the Best Pancreatic Tumor Contrast to Noise Ratio. Last author DOI 10.1016/s1001-9294(13)60003-6↗
  15. Anti-CXCR4 monoclonal antibody conjugated to ultrasmall superparamagnetic iron oxide nanoparticles in an application of MR molecular imaging of pancreatic canc… Co-author DOI 10.1258/ar.2012.120055↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huadan Xue · 13 shared papers, 2012–2025 · strength 1.92
  2. Liang Zhu · 5 shared papers, 2016–2025 · strength 0.88
  3. Jie Tian · 3 shared papers, 2019–2024 · strength 0.47
  4. Menghua Dai · 2 shared papers, 2021–2025 · strength 0.38
  5. Wenjia Zhang · 2 shared papers, 2022–2024 · strength 0.37
  6. Yuejuan Cheng · 2 shared papers, 2019–2025 · strength 0.36
  7. Sihang Cheng · 2 shared papers, 2019–2021 · strength 0.36
  8. Ming He · 2 shared papers, 2019–2025 · strength 0.35
  9. Zhiyong Liang · 2 shared papers, 2016–2025 · strength 0.31
  10. Zihe Wang · 1 shared paper, 2024 · strength 0.31
  11. Xinming Zhao · 1 shared paper, 2025 · strength 0.26
  12. Juan Li · 1 shared paper, 2025 · strength 0.22
  13. Huadan Xue · 1 shared paper, 2024 · strength 0.21
  14. Ming He · 1 shared paper, 2023 · strength 0.19
  15. Xiaolong Liang · 1 shared paper, 2022 · strength 0.16
  16. Ingolf Sack · 1 shared paper, 2021 · strength 0.12
  17. Yonglan He · 2 shared papers, 2013–2016 · strength 0.11
  18. Yun Wang · 1 shared paper, 2019 · strength 0.09
  19. Kai Lin Xu · 1 shared paper, 2019 · strength 0.09
  20. Dong Tang · 1 shared paper, 2019 · strength 0.08
  21. D. Wang · 1 shared paper, 2019 · strength 0.08
  22. X. Wang · 1 shared paper, 2016 · strength 0.06
  23. Arman Smakic · 1 shared paper, 2016 · strength 0.06
  24. Ge Chen · 1 shared paper, 2016 · strength 0.06
  25. Huanwen Wu · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.